Germline Genomics in Thyroid Cancer: Controversies in Variant Pathogenicity, Clinical Utility of Genetic Screening, and Challenges for Clinical Implementation
Germline genomics has transformed the understanding of hereditary susceptibility to thyroid cancer; however, uncertainty persists regarding variant pathogenicity, the clinical utility of genetic screening, and the implementation of genomic medicine. This critical narrative review examines hereditary susceptibility genes, variant classification, genetic risk assessment, and implementation barriers from an international perspective, with particular attention to Latin American populations. Published genetic investigations, clinical guidance, and variant interpretation frameworks are synthesized. The evidence distinguishes the well-established role of RET in hereditary medullary thyroid carcinoma from recognized syndromic associations involving PTEN, APC, and DICER1 and from candidate susceptibility genes, including CHEK2, HABP2, SEC23B, and SRGAP1, for which the strength of validation varies. Germline variant interpretation requires the integration of population allele frequencies, functional evidence, familial segregation, gene–disease validity, and independent replication. Underrepresentation of diverse populations, inconsistent genomic reference information, and unequal access to specialized testing and counseling may restrict clinical translation, particularly in Latin America. The review concludes that meaningful clinical utility depends on validated hereditary associations, rigorous pathogenicity assessment, and evidence-based management pathways rather than the mere detection of additional inherited variants.
Authors
- Mauricio Zuluaga (ORCID: https://orcid.org/0000-0003-0679-7375)
Publication Details
- Journal
- IECCMEXICO
- Published
- 2026-11-15
- DOI
- https://doi.org/10.64784/406
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00